| Drug Name: | Thalidomide (50-35-1) |
|---|---|
| PubChem ID: | 5426 |
| SMILES: | C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O |
| InchiKey: | UEJJHQNACJXSKW-UHFFFAOYSA-N |
| Therapeutic Category: | Angiogenesis Inhibitors, Angiogenesis Modulating Agents, Anti-Bacterial Agents, Anti-Infective Agents, Antineoplastic Agents, Growth Inhibitors, Growth Substances, Immunologic Factors, Immunosuppressive Agents, Leprostatic Agents, Noxae, Teratogens |
| Molecular Weight (dalton) | : | 258.233 |
| LogP | : | 0.0878 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 83.55 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Chlorpromazine (50-53-3) | Cns Depression | Additive | Thalidomide increases the effect of other CNS depressants, | Clinical pharmacokinetics of thalidomide |
| Darbepoetin alfa (209810-58-2) | Thromboembolic Event | Synergistic | Not understood | Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha |
| Doxorubicin (23214-92-8) | Deep Vein Thrombosis | Additive | Not understood | Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy |
| Peginterferon Alfa-2B (215647-85-1) | Bone Marrow Depression | Additive | severe suppression in this patient may have been due to the combined effects of the peginterferon and thalidomide | Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-?2a upon Progression |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Venous Thrombosis (Dvt) | Thrombomodulin (P07204) | Thrombomodulin showed significant variations between baseline and 1st-month values and 1st- and 3rd-month values@which leads to deep venous thrombosis (DVT) [ ADR Type 1 ] | Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category